# US 2019/0169611 A1 · dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169611 A1
- Document ID: US20190169611A1
- Status: Published application
- Kind: A1
- Application number: 16/028,878
- Filed: 2018-07-06
- Published: 2019-06-06
- Earliest claimed: 2010-09-03
- Assignees: Sarepta Therapeutics, Inc.
- Applicants: Sarepta Therapeutics, Inc.
- Inventors: Patrick L. Iversen
- Web page: https://patentgrep.com/patent/US20190169611A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/314: Phosphoramidates
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/3513: Protein; Peptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Morpholino oligomers containing modified intersubunit linkages and/or terminal groups are provided for use within dsRNA molecules. The oligomers are oligonucleotide analogs containing predetermined sequences of base-pairing moieties. Also provided are such oligomers conjugated to peptide transporter moieties, where the transporters are preferably composed of arginine subunits, or arginine dimers, alternating with neutral amino acid subunits.

## Claims

### Claim 1

A double-stranded ribonucleic acid (dsRNA) molecule for inhibiting the expression of a target gene in a cell, wherein said dsRNA comprises at least two sequences that are complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence comprising a region of complementarity which is substantially complementary to at least a part of a target gene mRNA, wherein said region of complementarity is less than about 30 nucleotides in length, wherein one or both of the sense and antisense strands comprise an oligomer backbone having at least one morpholino subunit joined by intersubunit linkages, wherein each morpholino subunit supports a base-pairing moiety, and wherein the intersubunit linkages comprise a structure selected from the group consisting of (A) and (B) below:
(A). an intersubunit linkage comprising the following structure (A-I):
where
W is S or O,
X═NR1R2 or OR6,
Y═O or NR7,
and each said linkage is selected from:
(a) uncharged linkage (a), where each of R1, R2, R6 and R7 is independently selected from hydrogen and lower alkyl;
(b1) cationic linkage (b1), where X═NR1R2 and Y═O, and NR1R2 represents an optionally substituted piperazino group, such that R1R2═—CHRCHRN(R3)(R4)CHRCHR—, where
each R is independently H or CH3,
R4 is H, CH3 or an electron pair, and
R3 is selected from H, lower alkyl, C(═NH)NH2, Z-L-NHC(═NH)NH2, and [C(O)CHR′NH]mH, where Z is carbonyl (C(O)) or a direct bond, L is an optional linker up to 18 atoms in length having bonds selected from alkyl, alkoxy, and alkylamino, R′ is a side chain of a naturally occurring amino acid or a one- or two-carbon homolog thereof, and m is 1 to 6;
(b2) cationic linkage (b2), where X═NR1R2 and Y═O, R1═H or CH3, and R2=LNR3R4R5, where L, R3, and R4 are as defined above, and R5 is H, lower alkyl, or lower (alkoxy)alkyl; and
(b3) cationic linkage (b3), where Y═NR7 and X═OR6, and R7=LNR3R4R5, where L, R3, R4 and R5 are as defined above, and R6 is H or lower alkyl;
and at least one said linkage is selected from cationic linkages (b1), (b2), and (b3); and
(B). an intersubunit linkage comprising the following structure (B-I):
where each of the intersubunit linkages (I) are selected from:
(a) linkage (a) wherein:
W is S or O;
X is —N(CH3)2; and
Y is O, and
(b) linkage (b) wherein:
W is S or O;
X is NR1R2 or OR3; and
Y is O or NR4,
wherein R1 is hydrogen or optionally substituted C2-C12 alkyl, each of R2, R3 and R4 is independently hydrogen or optionally C1-C12 alkyl, and wherein each of R1, R2, R3 and R4 may join with another of R1, R2, R3 or R4 to form an optionally substituted 5, 6 or 7-membered heterocycle comprising one or more N, O or S atoms or combinations thereof, and wherein at least one of the intersubunit linkages comprises linkage (b).

### Claim 2 (depends on 1)

The dsRNA molecule of claim 1, wherein said morpholino subunits have the structure:
where Pi is a base-pairing moiety, and said linkages connect the nitrogen atom of (i) to the 5′ carbon of an adjacent subunit.

### Claim at position 3

3-8. (canceled)

### Claim 9 (depends on 1)

The dsRNA molecule of claim 1, wherein each of R1 and R2, in linkages of type (a), is methyl.

### Claim 10 (depends on 1)

The dsRNA molecule of claim 1, wherein said oligomer includes at least two consecutive linkages of type (a).

### Claim 11 (depends on 1)

The dsRNA molecule of claim 1, having a length of about 10 to 30 base pairs.

### Claim 12 (depends on 1)

The dsRNA molecule of claim 1, having a length of about 15 to 25 base pairs.

### Claim 13 (depends on 1)

The dsRNA molecule of claim 1, wherein said cationic linkages are of type (b1), where each R is H, R4 is H, CH3, or an electron pair, and R3 is selected from H, CH3, C(═NH)NH2, and C(O)-L-NHC(═NH)NH2.

### Claim at position 9

14-17. (canceled)

### Claim 18 (depends on 1)

The dsRNA molecule of claim 1, wherein said cationic linkages are of type (b1), where each R is H, and each of R3 and R4 is independently H or CH3.

### Claim 19 (depends on 18)

The dsRNA molecule of claim 18, wherein each of R3 and R4 is H.

### Claim 20 (depends on 1)

The dsRNA molecule of claim 1, wherein said cationic linkages are of type (b2), where L is a linker up to 12 atoms in length having bonds selected from alkyl and alkylamino.

### Claim at position 13

21-31. (canceled)

### Claim 32 (depends on 1)

The dsRNA molecule of claim 1, wherein X is —NR1R2 and linkage (b) has the following structure (II):
wherein Z represents a 5, 6 or 7 membered optionally substituted heterocycle comprising one or more N, O or S atoms or combinations thereof.

### Claim 33 (depends on 32)

The dsRNA molecule of claim 32, wherein W and Y are each O.

### Claim 34 (depends on 32)

The dsRNA molecule of claim 32, wherein linkage (b) has one of the following structures (III), (IV), (V) or (VI):
wherein R5, R6 and R7 are each independently optionally substituted C1-C12 alkyl, (—NR8R9), —C(═O)R8—, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, —SR8, or C1-C12 alkoxy, wherein each of R8 and R9 are independently optionally substituted C1-C12 alkyl, —NR8R9, —C(═O)R8—, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, —SR8, or C1-C12 alkoxy.

### Claim at position 17

35-38. (canceled)

### Claim 39 (depends on 1)

The dsRNA molecule of claim 1, wherein linkage (b) is:
(b1) linkage (b1), wherein X=4-aminopiperidin-1-yl;
(b2) linkage (b2), wherein X═N-methyl-N-hexylamino;
(b3) linkage (b3), wherein X=4-N-(N-ibu-Cys)piperazin-1-yl;
(b4) linkage (b4), wherein X=4-N-(3,4,5-trimethoxybenzoyl)piperazin-1-yl;
(b5) linkage (b5), wherein X=4-N-pyrrolidinylpiperidin-1-yl;
(b6) linkage (b6), wherein X=4-N-(3-tetrazoylbenzoyl)piperazin-1-yl;
(b7) linkage (b7), wherein X=4-N-succinamidopiperazin-1-yl;
(b8) linkage (b8), wherein X=4-N-mercaptoacetylpiperazin-1-yl;
(b9) linkage (b9), wherein X=morpholino-4-yl;
(b10) linkage (b10), wherein X═S-2-methoxymethylpyrrolindin-1-yl;
(b11) linkage (b11), wherein X═R-2-methoxymethylpyrrolindin-1-yl;
(b12) linkage (b12), wherein X and Y may be taken together to form an optionally substituted heterocycle ring of 5,6 or 7 members comprising one or more N, O or S atoms or combinations thereof;
(b13) linkage (b13), wherein X=4-trimethylaminopiperidin-1-yl; or
(b14) linkage (b14), wherein X=4-guanidinylpiperidin-1-yl.

### Claim at position 19

40-43. (canceled)

### Claim 44 (depends on 1)

The dsRNA molecule of claim 1, wherein at least one of the sense and antisense strands comprise a 5′ terminal residue and/or a 3′ terminal residue, wherein the 5′ terminal residue and/or the 3′ terminal residue has a terminal structure as set out in the following structure (C-I):
wherein, independently at each occurrence:
R1 is absent, H or C1-C6 alkyl;
R2 and R3 are absent, H, a cell-penetrating peptide or R4;
R4 is optionally substituted C1-C30 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted aryl, optionally substituted C1-C30 aralkyl, optionally substituted C1-C30 alkylcarbonyl, optionally substituted C3-C8 cycloalkylcarbonyl, optionally substituted C3-C8 cycloalkylalkylcarbonyl, optionally substituted C1-C30 arylcarbonyl, optionally substituted C1-C30 aralkylcarbonyl, optionally substituted C1-C30 alkyloxycarbonyl, optionally substituted C3-C8 cycloalkyloxycarbonyl, optionally substituted C1-C30 aryloxycarbonyl or optionally substituted C1-C30 aralkyloxycarbonyl;
W is S or O;
X is NR5R6or OR7;
Y is O or NR8,
B is a base-pairing moiety;
L is an optional linker up to 18 atoms in length comprising bonds selected from alkyl, hydroxyl, alkoxy, alkylamino, amide, ester, carbonyl, carbamate, phosphorodiamidate, phosphoroamidate, phosphorothioate and phosphodiester; and
n is an integer of 0 or greater; and
wherein each of R5, R6, R7 and R8 is independently hydrogen or optionally substituted C1-C12 alkyl, and wherein each of R5, R6, R7 and R8 may join with another of R5, R6, R7or R8 to form an optionally substituted 5, 6 or 7-membered heterocycle comprising one or more N, O or S atoms or combinations thereof; and wherein at least one of R2 or R3 is R4, and provided that both of R1 and R2 are not absent.

### Claim at position 21

45-89. (canceled)

### Claim 90 (depends on 1)

A method of inhibiting production of a protein comprising exposing a nucleic acid encoding the protein to a dsRNA molecule of claim 1.
